User: TahirAmin Topic: IP
Category: drugs :: everywhere
Last updated: Jun 16 2018 21:25 IST RSS 2.0
 
1 to 20 of 10,053    
Dr. Reddy’s new drug hits legal hurdle 16.6.2018 Hindu: Policy & Issues
U.S. court issues restraint order following patent litigation over Suboxone
Also found in: [+]
Apple patents BP monitoring 'cuff' 8.6.2018 Sify Finance
Apple has patented a design for a wearable blood pressure monitor -- a cuff, equipped with a sensor that is expected to be Bluetooth compatible and sport a touchscreen.
Also found in: [+]
Gap in regulating biotech drug copies prompts WHO to step in 30.5.2018 General News
LONDON (Reuters) - Cut-price copies of expensive biotech drugs promise to slash the cost of treating serious diseases, including cancer, in rich and poor countries alike - but uneven regulation has created a lopsided market.
Also found in: [+]
AstraZeneca opens another medicines development centre 30.5.2018 General News
Bio-pharmaceutical company AstraZeneca officially opened its new Global Medicines Development (GMD) centre here today. The unit is one of AstraZeneca's nine GMD centres that the company has around the world that transforms breakthrough molecules into medicines and monitors their use and safety, the company said in a press release. With this opening, India would now play an even bigger role in AstraZeneca's global operations, the release said. The GMD Bengaluru team would focus on supporting AstraZeneca's medicines which covers treatments across a range of therapies, including oncological, respiratory and cardiovascular and metabolic diseases, it said. GMD Bengaluru plays a key role supporting 51 of AstraZenecas mature brands which are used by patients around the world. Last year, the team recruited scientific experts in the fields of regulatory science, clinical, and patient safety, and has grown from 30 to 70 people. The expansion would see a further increase to more ...
Also found in: [+]
Roche, chasing Merck, notches another lung cancer win 29.5.2018 General News
ZURICH (Reuters) - Roche's bid to keep Merck's cancer blockbuster Keytruda within striking distance got a lift on Tuesday when the Swiss drugmaker said its immunotherapy Tecentriq mixed with chemotherapy boosted lung cancer patients' survival.
Also found in: [+]
EU makes it easier for companies to produce generic medicines for export 28.5.2018 General News
BRUSSELS (Reuters) - The European Commission on Monday proposed to change intellectual property rules to let pharmaceutical companies produce generic drugs for export to countries and regions where they are not under extended patent protection.
Also found in: [+]
Dr. Reddy’s arm files patent infringement lawsuit 26.5.2018 Hindu: Hyderabad
Promius Pharma LLC, a wholly owned subsidiary of Dr. Reddy’s Laboratories, has filed a lawsuit for patent infringement in a US court against Perrigo U
Also found in: [+]
Sun Pharma warns U.S. pricing pressure to hit 2019 profit 25.5.2018 General News
(Reuters) - India's largest drugmaker Sun Pharmaceutical Industries Ltd said on Friday it expects its 2019 revenue to come in short of analysts' expectations due to pricing pressure in its main market, the United States.
Also found in: [+]
Dr Reddy'sfiles patent infringement case againstPerrigo UK & 25.5.2018 General News
Dr Reddy's Laboratories Limited today said subsidiary Promius Pharma LLC, has filed a patent infringement lawsuit in a US court against Perrigo UK Finco Limited Partnership, Perrigo Israel Pharmaceuticals Ltd. and Taro Pharmaceuticals, Inc over its topical spray Sernivo. In a filing with the bourses,it said the case was filed in the United States District Court for Eastern District of Texas against the three companies "in response to two paragraph-IV notice letters received for its twice daily topical spray Sernivo (betamethasone dipropionate, 0.05%) product." A notice under Paragrap IV will be issued to a patent holder when a generic company wants to make a similar drug. Promius said it anticipates this lawsuit will trigger a 30 month stay of Food and Drug Administration approval of Perrigo's and Taro's Abbreviated New Drug Application (ANDA). Sernivo spray is protected by six Orange Book patents that expire in 2030. The publication Approved Drug Products with Therapeutic
Also found in: [+]
Dr Reddys Laboratories' subsidiary files lawsuit for patent infringement in US 25.5.2018 General News
SERNIVO spray, 0.05% is protected by six Orange Book patents that expire in 2030. Promius will continue to vigorously defend its SERNIVO intellectual property rights against infringement wherever they are challenged
Also found in: [+]
CSIR bags the Clarivate Analytics India Innovation Award 2018 in the Government Research Organizations Category 24.5.2018 Govt of india: PIB
Council of Scientific & Industrial Research has been awarded the Clarivate Analytics India Innovation Award 2018 in the Government Research Organizations Category. This award yet again recognizes CSIR as the top innovator.
Also found in: [+]
CCI approves USD 66 bn Bayer-Monsanto deal 22.5.2018 General News
Fair trade regulator CCI has approved the German giant Bayer's proposed USD 66 billion acquisition of US-based biotech firm Monsanto, subject to certain modifications to the long-pending deal. The approval to the deal, announced in September 2016, assumes significance in the wake of Monsanto facing opposition from various quarters within India over promotion of genetically modified crops, as also over royalty and patent issues. The clearance from the Competition Commission of India (CCI) is one of the several regulatory approvals required by Bayer in various countries to close the deal. Announcing its approval today, the CCI tweeted that it has cleared "acquisition of Monsanto by Bayer AG, subject to compliance of certain modifications". Mergers and acquisitions beyond a certain threshold require approval of the CCI. India is one of the 30 countries whose approval is needed for the merger of worldwide operations of the two companies. The major approvals still required are from the US .
Also found in: [+]
Smruthi Organics reports standalone net loss of Rs 4.66 crore in the March 2018 quarter 21.5.2018 General News
Sales rise 38.06% to Rs 30.25 crore
Also found in: [+]
Trinity League India standalone net profit rises 293.75% in the March 2018 quarter 17.5.2018 General News
Sales rise 440.00% to Rs 0.81 crore
Also found in: [+]
Ayushman Bharat may help patients access life-saving drugs 16.5.2018 Rediff: Top Stories (India)
'We have often heard the mythical argument that patents block access to life-saving drugs, but only 5% of medicines from multinational companies are under patent protection in India.''Where these patented products are beyond the reach of Indian patients, the companies have programmes to facilitate access to their drugs, for free or for a fraction of the price,' points out Ranjana Smetacek, former director general, Organisation of Pharmaceutical Producers of India.
Also found in: [+]
Reward innovation 12.5.2018 Hindu: Internet
A robust intellectual property rights (IPR) framework, with suitable enforcement systems, is critical to support India’s efforts to be a global leade
Also found in: [+]
'Indian IP and liabilities law barrier to pharma R&D investment' 10.5.2018 General News
India's intellectual property regulations and liabilities laws pose a major barrier to foreign companies, specially from the US, that prevents them from increasing their footprint in the country's huge market, pharma sector leaders have said. Andrew Plump, chief medical and scientific officer of Takeda Pharmaceuticals, a major Japanese drugmaker, said his company has a very limited presence in India. "But it is open to increase its footprint in India, with the improvement in IP protection laws and those related to liabilities," Plump said. "I think more and more there's an intent in India to try to open up its doors. I think if that happens, and if it facilitates entry of innovative patent protected pharmaceuticals you will see value driven companies coming into India," Plump told PTI on the sidelines of the 12th annual biopharma and healthcare summit here. "Historically it (IP sector regulations and liabilities law) has been not just a hindrance but a barrier and impediment (for the .
Also found in: [+]
Japanese drug maker Takeda to buy Ireland's Shire 8.5.2018 General News
Japanese drugmaker Takeda has agreed to buy Shire for 46 billion pounds (USD 62.4 billion) in cash and stock, one of the biggest deals ever in the pharmaceuticals industry, the companies said today. Takeda will pay the equivalent of 49.01 pounds in cash and stock for each share of Shire, based on Takeda's closing share price on April 23, the day before a preliminary deal was announced. Shire gives Takeda a larger presence in the US and expertise in rare diseases, an increasingly important area for pharmaceutical companies as patents on established drugs expire. Even though Shire's headquarters are in Dublin, it earns more than two thirds of its revenue in the US on drugs like Adderall, which is used for ADHD. Takeda, meanwhile, has like many Japanese companies been expanding overseas to compensate for slowing growth at home. Last year it bought Ariad Pharmaceuticals of Cambridge, Massachusetts. Takeda is valued at about USD 34 billion and makes almost half of its sales in Asia, and ...
Also found in: [+]
Prabhu urges pharma firms to do more R&D, develop new markets 8.5.2018 All News-IANS Stories
Indian pharmaceutical companies need to increase R&D investments and develop new markets in order to boost their exports, Commerce Minister Suresh Prabhu said on Tuesday.
Also found in: [+]
Samsung BioLogics loses $6 billion in stocks dive after notice of accounting breach 2.5.2018 General News
SEOUL (Reuters) - Shares in Samsung BioLogics Co Ltd tumbled nearly 20 percent on Wednesday, losing almost $6 billion in value in their biggest daily intra-day fall, after South Korea's financial watchdog provisionally decided it had breached an accounting rule.
Also found in: [+]
1 to 20 of 10,053